Huntington Disease: Brief Overview

Abstract

An aberrant growth of the CAG nucleotide causes Huntington's disease (HD), a deadly neurological illness. HD cannot be reversed, reduced, or stopped despite encouraging preclinical advances in therapeutic treatments focused at lowering mutant HTT protein. Tetrabenazine TBZ, an antagonist of vesicular monoamine transporter 2, is major medication licensed by F.D.A for cure of HD (VMAT2). There are some hope with gene based therapies like ASO [antisense oligonucleotides] and CRISPR-Cas9 gene-editing system. Gene modifying therapies also in the progressive phase. This chapter gives information about Causes, clinical symptoms, probable treatment and challenges about Huntington’s disease.